白云山分公司收到药品生产许可证
财中社2月12日电白云山（600332/00874）发布公告，近日，公司分公司何济公药厂收到广东省药品监督管理局核准签发的《药品生产许可证》，同意核减生产线。此次变更涉及何济公药厂在广州市从化明珠工业园的F栋生产线，该生产线的生产范围为中药前处理及提取车间。核减生产线的原因是为了进行部分产能调整，以优化公司资源配置，继续保持稳定的生产能力，满足市场需求。
公告中提到，此次获得的《药品生产许可证》对公司的当期业绩无重大影响。需要注意的是，医药产品的生产和销售受到市场环境变化等因素的影响，存在一定的不确定性，投资者需谨慎决策并防范投资风险。
2024年前三季度，白云山实现收入590.60亿元，归母净利润31.59亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10